Moderna to Present at Upcoming Conferences in December 2024
Moderna (MRNA) has announced its upcoming participation in two major investor conferences in December 2024. The company will present at the 7th Annual Evercore ISI HealthCONx Conference on December 4th at 1:20pm ET, followed by the Piper Sandler 36th Annual Healthcare Conference on December 5th at 10:30am ET.
Live webcasts of both presentations will be accessible through the Investors section of Moderna's website under 'Events and Presentations.' Recordings will remain available for at least 30 days after each presentation.
Moderna (MRNA) ha annunciato la sua partecipazione a due importanti conferenze per investitori a dicembre 2024. L'azienda presenterà alla 7ª Conferenza Annuale Evercore ISI HealthCONx il 4 dicembre alle 13:20 ET, seguita dalla 36ª Conferenza Annuale Healthcare di Piper Sandler il 5 dicembre alle 10:30 ET.
I webcast dal vivo di entrambe le presentazioni saranno accessibili attraverso la sezione Investitori del sito web di Moderna sotto 'Eventi e Presentazioni.' Le registrazioni rimarranno disponibili per almeno 30 giorni dopo ciascuna presentazione.
Moderna (MRNA) ha anunciado su próxima participación en dos importantes conferencias para inversores en diciembre de 2024. La compañía presentará en la 7ª Conferencia Anual Evercore ISI HealthCONx el 4 de diciembre a la 1:20 p.m. ET, seguida de la 36ª Conferencia Anual de Salud de Piper Sandler el 5 de diciembre a las 10:30 a.m. ET.
Las transmisiones en vivo de ambas presentaciones estarán disponibles a través de la sección de Inversores en el sitio web de Moderna bajo 'Eventos y Presentaciones.' Las grabaciones estarán accesibles durante al menos 30 días después de cada presentación.
모더나 (MRNA)는 2024년 12월에 열리는 두 개의 주요 투자자 회의에 참여할 것이라고 발표했습니다. 회사는 12월 4일 오후 1시 20분 ET에 제7회 에버코어 ISI 헬스CONx 회의에서 프레젠테이션을 하며, 12월 5일 오전 10시 30분 ET에 파이퍼 샌들러 제36회 헬스케어 회의에서도 발표를 진행합니다.
두 발표의 라이브 웹캐스트는 모더나 웹사이트의 투자자 섹션에서 '이벤트 및 발표'를 통해 접근할 수 있습니다. 각 프레젠테이션 후 최소 30일 동안 녹화된 내용도 제공됩니다.
Moderna (MRNA) a annoncé sa participation prochaine à deux grandes conférences pour investisseurs en décembre 2024. L'entreprise présentera à la 7ème Conférence Annuelle Evercore ISI HealthCONx le 4 décembre à 13h20 ET, suivie de la 36ème Conférence Annuelle Healthcare de Piper Sandler le 5 décembre à 10h30 ET.
Les webcasts en direct des deux présentations seront accessibles via la section Investisseurs du site Web de Moderna sous 'Événements et Présentations.' Les enregistrements resteront disponibles pendant au moins 30 jours après chaque présentation.
Moderna (MRNA) hat seine bevorstehende Teilnahme an zwei wichtigen Investorenkonferenzen im Dezember 2024 angekündigt. Das Unternehmen wird am 4. Dezember um 13:20 Uhr ET bei der 7. Jahrestagung der Evercore ISI HealthCONx präsentieren, gefolgt von der 36. Jahrestagung im Gesundheitswesen von Piper Sandler am 5. Dezember um 10:30 Uhr ET.
Live-Webcasts beider Präsentationen sind über den Bereich Investoren auf der Website von Moderna unter 'Veranstaltungen und Präsentationen' zugänglich. Aufzeichnungen bleiben mindestens 30 Tage nach jeder Präsentation verfügbar.
- None.
- None.
CAMBRIDGE, MA / ACCESSWIRE / November 25, 2024 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences:
7th Annual Evercore ISI HealthCONx Conference, on Wednesday, December 4th at 1:20pm ET
Piper Sandler 36th Annual Healthcare Conference, on Thursday, December 5th at 10:30am ET
A live webcast of each of these presentations will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of each webcast will be archived on Moderna's website for at least 30 days following the presentation.
About Moderna
Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.
Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com
SOURCE: Moderna, Inc.
View the original press release on accesswire.com
FAQ
When is Moderna (MRNA) presenting at the Evercore ISI HealthCONx Conference in December 2024?
What time is Moderna's (MRNA) presentation at the Piper Sandler Healthcare Conference in December 2024?
How long will Moderna's (MRNA) December 2024 conference webcasts be available for replay?
Where can I watch Moderna's (MRNA) December 2024 investor conference presentations?
